Clinical Data for CTLA-4 Therapy in Squamous NSCLC

In this segment, the panel reviews additional clinical data from the initial stage of the trial evaluating next-generation CTLA-4-directed therapy in advanced squamous non-small cell lung cancer (NSCLC). Dr. Narjust Florez discusses data with a median follow-up of 14.5 months, noting similar median progression-free survival between the investigational therapy and docetaxel groups, while median overall survival had not yet been reached in the available analysis. The panel highlights an overall survival hazard ratio of 0.46 and a higher overall response rate with the investigational therapy, including more partial responses and stable disease compared with docetaxel. However, the experts emphasize that these findings remain hypothesis-generating. Dr. Florez and Dr. Christian Rolfo note that the confidence interval around the hazard ratio is wide and that the initial stage included a relatively small number of patients. The panel stresses that response rate alone does not establish durability and that longer follow-up is needed to determine the duration of benefit. The discussion also considers how efficacy, durability, and toxicity will collectively inform interpretation of the subsequent trial data.